Aptar Pharma Archives - Medical Design Sourcing

Aptar wins FDA contract to study low global warning potential metered dose inhalers

[Image courtesy of Aptar]Aptar Pharma announced today that it entered into a contract with the FDA to work on low global warming potential (low-GWP) inhalers.

The FDA enlisted Aptar intends to study the challenges of developing low-GWP propellant metered dose inhalers (MDIs). The Crystal Lake, Illinois-based company expects its study to help define the potential target product profile of low-GWP propellant MDIs. It hopes to achieve comparability in critical quality attributes to existing MDIs.

Aptar values the contracted work, which includes “optional contract line items,” at approximately $6 million.

Get the full story at our sister site, Drug Delivery Business News.

Aptar Pharma launches metal-free nasal spray pump

The APF Futurity nasal spray pump. [Image courtesy of Aptar Pharma]Aptar Pharma announced today that it launched its first metal-free, multidose nasal spray pump, called the APF Futurity.

Crystal Lake, Illinois-based Aptar developed APF Futurity to deliver nasal saline and other comparable over-the-counter (OTC) formulations. The company designed the pump specifically for recyclability.

Get the full story at our sister site, Drug Delivery Business News.

FDA approves first nasally administered pharmaceutical treatment for dry eye

[Image from Aptar Pharma]AptarGroup (NYSE:ATR) announced today that it received FDA approval for its nasal pump to deliver a pharmaceutical treatment for dry eye.

Crystal Lake, Illinois-based Aptar’s patented Cartridge Pump System (CPS), designed for the multidose delivery of preserved and non-preserved drug formulations, received approval as the device for delivering Oyster Point Pharma’s Tyrvaya (varenicline solution) nasal spray (0.03 mg).

Get the full story at our sister site, Drug Delivery Business News.